Vaccinex (United States)

Homepage: vaccinex.com

ROR: 047jxj944

OpenAlex ID: I4210141595

Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene

2006 · Yasuhiko Nishio, Yufeng Dong, et al. · Gene · 346

A biological classification of Huntington's disease: the Integrated Staging System

2022 · Sarah J Tabrizi, Scott Schobel, et al. · The Lancet Neurology · 342

PDF

Articular Cartilage Biology

2003 · Michael Ulrich-Vinther, Michael D. Maloney, et al. · Journal of the American Academy of Orthopaedic Surgeons · 278

CXCL13 antibody for the treatment of autoimmune disorders

2015 · Ekaterina Klimatcheva, Tracy Pandina, et al. · BMC Immunology · 125

PDF

SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease

2014 · Ernest S. Smith, Alan Jonason, et al. · Neurobiology of Disease · 121

PDF

CXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesis

2013 · Jill M Kramer, Ekaterina Klimatcheva, et al. · Journal of Leukocyte Biology · 120

A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

2009 · Mariateresa Fulciniti, Teru Hideshima, et al. · Clinical Cancer Research · 119

PDF

Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies

2015 · Elizabeth E. Evans, Alan S. Jonason, et al. · Cancer Immunology Research · 111

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease

2015 · Amber L. Southwell, Sonia Franciosi, et al. · Neurobiology of Disease · 109

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk

2010 · E Katz, S Dubois-Marshall, et al. · British Journal of Cancer · 76

PDF

Sustained activation and tumor targeting of NKT cells using a CD1d–anti-HER2–scFv fusion protein induce antitumor effects in mice

2008 · Kathrin Stirnemann, Jackeline F. Romero, et al. · Journal of Clinical Investigation · 69

PDF

Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

2022 · Andrew Feigin, Elizabeth E. Evans, et al. · Nature Medicine · 65

PDF

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

2015 · Amita Patnaik, Glen J. Weiss, et al. · Clinical Cancer Research · 65

Transforming Growth Factor-β and Wnt Signals Regulate Chondrocyte Differentiation through Twist1 in a Stage-Specific Manner

2007 · Yu-Feng Dong, Do Y. Soung, et al. · Molecular Endocrinology · 59

PDF

Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function

2018 · Paul E. Clavijo, Jay Friedman, et al. · Cancer Immunology Research · 58

Generation and preclinical characterization of an antibody specific for SEMA4D

2015 · Terrence L. Fisher, Christine A. Reilly, et al. · mAbs · 55

C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer

2006 · Elizabeth E. Evans, Alicia D. Henn, et al. · Molecular Cancer Therapeutics · 55

Clinal patterns of desiccation and starvation resistance in ancestral and invading populations of Drosophila subobscura

2008 · George W. Gilchrist, Lisa M. Jeffers, et al. · Evolutionary Applications · 52

PDF

Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection

2014 · K Yamamoto, S Nishiumi, et al. · Mucosal Immunology · 48

PDF

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity

2022 · Elizabeth E. Evans, Vikas Mishra, et al. · Journal of Neuroinflammation · 41

PDF

Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody

2015 · John E. Leonard, Terrence L. Fisher, et al. · Molecular Cancer Therapeutics · 36

PDF

CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses

2012 · Stéphanie Corgnac, Rachel Perret, et al. · Cancer Immunology Immunotherapy · 36

PDF

Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction

2016 · Arjun Sharma, Jeremy Kiripolsky, et al. · Clinical Immunology · 35

PDF

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer

2021 · Michael R. Shafique, Terrence L. Fisher, et al. · Clinical Cancer Research · 32

Prior exposure of mice to Fusobacterium nucleatum modulates host response to Porphyromonas gingivalis

2001 · J. Choi, M. A. Borrello, et al. · Oral Microbiology and Immunology · 30

Works count: 142

Citation count: 16,290